Product Images Gabapentin

The text describes various packages of Gabapentin Capsules, USP 300mg manufactured for Cipla USA, Inc. The packages have different quantities (30, 60, 90, or 240). Each package has a unique NDC number, lot number, and batch number. The capsules are yellow and are RX drugs that require a prescription to dispense. The caution message from the package insert warns about the prohibition of dispensing without prescription and the need to store at a certain temperature range.*

This is a table detailing the recommended Gabapentin dosage based on renal function. The table lists the total daily dose range in milligrams (mg) for patients with varying degrees of renal function based on their creatinine clearance. Patients on hemodialysis require additional supplemental doses. The table also provides dosage frequency information (e.g. TID, BID, QD) and a formula for estimating creatinine clearance using the Cockcroft and Gault equation.*

This appears to be a table showing the risk of antiepileptic drugs for different indications, including epilepsy and psychiatric disorders. The table shows the number of patients with events per 1,000 patients for both placebo and drug groups, as well as the relative risk and risk difference.*

This is a table which shows the percentage of adverse reactions in a group of people who took Gabapentin and another group who took Placebo in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia. The table categorizes the adverse reactions into different systems such as Body as a whole, Digestive system, Metabolic and Nutritional disorders, Nervous system, Respiratory system, Special senses, and reports on different adverse reactions in each group.*

This is a table showing adverse reactions observed in epilepsy patients of age greater than 12 years in pooled placebo-controlled add-on trials. The table has columns for Gabapentin (N=543) and Placebo (N=378) and lists various adverse reactions and their percentage occurrence. The adverse reactions are categorised under different organ systems such as Body As A Whole, Cardiovasoular, Digestive System, Nervous System, Respiratory System, Skin, and Appendages, Urogenttal System and Special Senses. In addition to this, the table also provides additional information about certain adverse reactions such as Amblyopia.*

This is a table that shows the adverse reactions observed in a placebo-controlled add-on trial of Gabapentin in pediatric epilepsy patients between the ages of 3 and 12. There were 110 patients who received Gabapentin and 128 who received placebo as part of their anti-epileptic drug therapy. The table shows the percentage of patients who experienced each type of adverse reaction for each group, including body weakness, viral infection, fever, increased weight, fatigue, nausea and vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection.*

This is a table presenting information on controlled studies that were conducted on Gabapentin, a medication used to treat pain associated with nerve damage. The table includes details on the duration of the studies, the dosages of Gabapentin administered to patients, and the number of patients receiving Gabapentin and a placebo. The medication was given in three divided doses per day.*